Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO, JESPECT) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study.

Trial Profile

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO, JESPECT) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs IC 51 (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Registrational
  • Sponsors Valneva
  • Most Recent Events

    • 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Dec 2013 Planned end date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT01047839).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top